<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>21571242</identifier>
<setSpec>1578-2190</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Sanmartín, V</dc:author>
<dc:author>Aguayo, R</dc:author>
<dc:author>Baradad, M</dc:author>
<dc:author>Casanova, J M</dc:author>
<dc:description xml:lang="en">Giant basal cell carcinoma (BCC) is defined as a tumor with a diameter of 5 cm or more. Surgery, the treatment of choice for any type of BCC, can cause considerable anatomical damage in large tumors. In 2 patients with giant BCC we therefore provided neoadjuvant treatment with a combination of oral acitretin and topical 5% imiquimod. Acitretin is a systemic retinoid used for primary prevention of nonmelanoma skin cancer. Imiquimod is an immunomodulator whose approved indications include treatment of nonfacial superficial BCC less than 2 cm in diameter. Previous studies have demonstrated a synergic anticancer effect of both drugs in vitro and in vivo. This combination produced a marked reduction in tumor mass in our patients. Later we were able to provide definitive treatment, which achieved complete remission of the tumors.</dc:description>
<dc:type>Case Reports</dc:type>
<dc:language>es</dc:language>
<dc:date>2012 Mar </dc:date>
<dc:title xml:lang="es">Tratamiento neoadyuvante con acitretino oral e imiquimod tópico en el carcinoma basocelular gigante.</dc:title>
<dc:title xml:lang="en">[Oral acitretin and topical imiquimod as neoadjuvant treatment for giant basal cell carcinoma].</dc:title>
<dc:publisher>Actas dermo-sifiliograficas</dc:publisher>
</metadata>
</record>
</pubmed-document>
